Procomvax (haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine)
- Region
- 🇪🇺 EU
- Active substance
- haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
- Company
- Sanofi Pasteur MSD, SNC
- Status
- Expired
- Therapeutic area
- Hepatitis B; Meningitis, Haemophilus; Immunization
- EU approval
- Fri 07 May 1999
- Application
- EMEA/H/C/000231
- ATC
- J07CA
- Official record
- www.ema.europa.eu
Indication
PROCOMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age.
Regulatory milestones
No milestones recorded in the last year.
Follow Procomvax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.